Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
TRIB1 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q96RU8 |
|---|---|
| Clone Names | 6030104 |
| Gene ID | 10221 |
|---|---|
| Other Names | Tribbles homolog 1, TRB-1, G-protein-coupled receptor-induced gene 2 protein, GIG-2, SKIP1, TRIB1 (HGNC:16891) |
| Target/Specificity | The synthetic peptide sequence used to generate the antibody AP7726b was selected from the C-term region of human TRIB1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | TRIB1 (HGNC:16891) |
|---|---|
| Function | Adapter protein involved in protein degradation by interacting with COP1 ubiquitin ligase (PubMed:27041596). The COP1- binding motif is masked by autoinhibitory interactions with the protein kinase domain (PubMed:26455797). Serves to alter COP1 substrate specificity by directing the activity of COP1 toward CEBPA (PubMed:27041596). Binds selectively the recognition sequence of CEBPA (PubMed:26455797). Regulates myeloid cell differentiation by altering the expression of CEBPA in a COP1-dependent manner (By similarity). Controls macrophage, eosinophil and neutrophil differentiation via the COP1-binding domain (By similarity). Interacts with MAPK kinases and regulates activation of MAP kinases, but has no kinase activity (PubMed:15299019, PubMed:26455797). |
| Tissue Location | Expressed in most human tissues with the highest levels in skeletal muscle, thyroid gland, pancreas, peripheral blood leukocytes, and bone marrow. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
TRIB1 antibody, also called gprotein coupled receptor induced, skip1, gig2, c8fwATP, functions in binding protein binding, protein kinase inhibitor activity, and protein serine/threonine kinase activities.Overexpression of TRIB1 in HeLa cells repressed the basal activity of the IL8 promoter by inhibiting AP1 activity. Overexpression of TRIB1 inhibited oncogenic Ras -driven AP1 activation and MEKK1-mediated AP1 activation. ERK activation was enhanced by TRIB1. Coimmunoprecipitation and yeast 2-hybrid assays showed that MEK1 interacted with both TRIB1 and TRIB3, and MKK4 interacted specifically with TRIB1. Cotransfection of MKK4 enhanced the level of TRIB1, indicating that the TRIB-MAPKK interaction stabilized TRIB1.
References
Kiss-Toth, E., et al., J. Biol. Chem. 279(41):42703-42708 (2004).Wu, M., et al., J. Biol. Chem. 278(29):27072-27079 (2003).Wilkin, F., et al., Eur. J. Biochem. 248(3):660-668 (1997).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
